| Year |
Citation |
Score |
| 2019 |
Stefka AT, Johnson D, Rosebeck S, Park JH, Nakamura Y, Jakubowiak AJ. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Medicine. PMID 31714026 DOI: 10.1002/Cam4.2695 |
0.398 |
|
| 2019 |
Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. British Journal of Haematology. PMID 31124580 DOI: 10.1111/Bjh.15969 |
0.329 |
|
| 2017 |
Jakubowiak AJ, Raje N, Vij R, Reece D, Berdeja JG, Stephens L, Tinari KM, Rosenbaum CA, Jasielec JK, Richardson PG, Gurbuxani S, Nam J, Severson E, McIver A, Wolfe B, ... ... Rosebeck S, et al. High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial Blood. 130: 4533-4533. DOI: 10.1182/Blood.V130.Suppl_1.4533.4533 |
0.303 |
|
| 2016 |
Jakubowiak A, Jasielec J, Rosenbaum CA, Cole CE, Chari A, Nam J, Severson E, Stephens LA, McDonnell K, Rosebeck S, Zimmerman T, Karrison T, Zonder J. Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 128: 973-973. DOI: 10.1182/Blood.V128.22.973.973 |
0.326 |
|
| 2016 |
Zimmerman T, Raje NS, Vij R, Reece D, Berdeja JG, Stephens LA, McDonnell K, Rosenbaum CA, Jasielec J, Richardson PG, Gurbuxani S, Nam J, Severson E, Wolfe BD, Rosebeck S, et al. Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Blood. 128: 675-675. DOI: 10.1182/Blood.V128.22.675.675 |
0.323 |
|
| 2015 |
Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum S, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase 10-dependent Apoptosis by Carfilzomib and Selinexor. Molecular Cancer Therapeutics. PMID 26637366 DOI: 10.1158/1535-7163.Mct-15-0488 |
0.455 |
|
| 2015 |
Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJ. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. British Journal of Haematology. 170: 66-79. PMID 25824111 DOI: 10.1111/Bjh.13394 |
0.393 |
|
| 2015 |
Zimmerman TM, Griffith KA, Jasielec J, Rosenbaum CA, McDonnell K, Waite-Marin J, Berdeja JG, Raje NS, Reece DE, Vij R, Alonge M, Rosebeck S, Gurbuxani S, Faham M, Kong KA, et al. Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). Journal of Clinical Oncology. 33: 8510-8510. DOI: 10.1200/Jco.2015.33.15_Suppl.8510 |
0.325 |
|
| 2015 |
Jakubowiak A, Jasielec J, Rosenbaum CA, Zonder JA, Cole CE, Chari A, Nam J, Stephens LA, McDonnell K, Uribe R, Rosebeck S, Rashal T, Youssoufian H, Henry S, Shacham S, et al. Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM) Blood. 126: 4223-4223. DOI: 10.1182/Blood.V126.23.4223.4223 |
0.331 |
|
| 2014 |
Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM. The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling. Oncogene. 33: 2520-30. PMID 23770847 DOI: 10.1038/Onc.2013.195 |
0.334 |
|
| 2014 |
Rosebeck S, Alonge M, Jasielec J, Mayampurath A, Volchenboum SL, Shacham S, Kauffman M, Jakubowiak A. Gene Expression and Transcription Factor (TF) Activation Profiling Identifies Suppression of Multiple Myeloma (MM) Cell Survival and Chemoresistance Pathways By Inhibition of XPO1/CRM1-Dependent Nuclear Export with Selinexor Blood. 124: 3444-3444. DOI: 10.1182/Blood.V124.21.3444.3444 |
0.383 |
|
| 2014 |
Rosebeck S, Alonge M, Jasielec J, McCauley D, Shacham S, Kauffman M, Jakubowiak A. Anti-Myeloma Activity of Combined Inhibition of the Proteasome with Carfilzomib (CFZ) and XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330) Via a Novel Mechanism of Intracellular Activation of Caspase 10-Dependent Apoptosis Blood. 124: 3443-3443. DOI: 10.1182/Blood.V124.21.3443.3443 |
0.458 |
|
| 2014 |
Vliet Mv, Jasielec J, Dytfeld D, Vij R, Dumee B, Bosman L, deBest LCM, Alonge M, Rosebeck S, Kandarpa M, McDonnell K, Griffith KA, Beers EHv, Jakubowiak A. Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Blood. 124: 2141-2141. DOI: 10.1182/Blood.V124.21.2141.2141 |
0.3 |
|
| 2014 |
Jasielec J, Dytfeld D, Griffith KA, McDonnell K, Lebovic D, Kandarpa M, Anderson T, Mietzel M, Faham M, Lee L, Levy J, Alonge M, Rosebeck S, Kaminski M, Jakubowiak A. Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd) Blood. 124: 2127-2127. DOI: 10.1182/Blood.V124.21.2127.2127 |
0.314 |
|
| 2013 |
Jasielec J, Dytfeld D, Griffith KA, McDonnell K, Lebovic D, Kandarpa M, Vesole DH, Jagannath S, Mietzel MA, Vij R, Faham M, Lee L, Beers EHv, Vliet MHv, Levy J, ... ... Rosebeck S, et al. Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM) Blood. 122: 3220-3220. DOI: 10.1182/Blood.V122.21.3220.3220 |
0.311 |
|
| 2013 |
Rosebeck S, Kandarpa M, Alonge MM, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ. Effects Of Inhibition Of XPO1/CRM1-Dependent Nuclear Export By Selinexor (KPT-330), Alone and In Combination With Carfilzomib (CFZ), On Apoptosis and Autophagy In Multiple Myeloma (MM) Blood. 122: 279-279. DOI: 10.1182/Blood.V122.21.279.279 |
0.479 |
|
| 2011 |
Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM. From MALT lymphoma to the CBM signalosome: three decades of discovery. Cell Cycle (Georgetown, Tex.). 10: 2485-96. PMID 21750409 DOI: 10.4161/Cc.10.15.16923 |
0.315 |
|
| 2011 |
Rosebeck S, Sudini K, Chen T, Leaman DW. Involvement of Noxa in mediating cellular ER stress responses to lytic virus infection. Virology. 417: 293-303. PMID 21742363 DOI: 10.1016/J.Virol.2011.06.010 |
0.533 |
|
| 2011 |
Rosebeck S, Lucas PC, McAllister-Lucas LM. Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncology (London, England). 7: 613-7. PMID 21568677 DOI: 10.2217/Fon.11.35 |
0.304 |
|
| 2011 |
Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science (New York, N.Y.). 331: 468-72. PMID 21273489 DOI: 10.1126/Science.1198946 |
0.339 |
|
| 2008 |
Rosebeck S, Leaman DW. Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis : An International Journal On Programmed Cell Death. 13: 562-72. PMID 18330707 DOI: 10.1007/S10495-008-0190-0 |
0.594 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2017 |
Stefka A, Johnson D, Rosebeck S, Park J, Nakamura Y, Jakubowiak AJ. Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models Blood. 130: 4415-4415. DOI: 10.1182/Blood.V130.Suppl_1.4415.4415 |
0.284 |
|
| 2016 |
Zimmerman TM, Griffith K, Jasielec JK, Rosenbaum CA, Berdeja JG, Vij R, Raje N, Reece DE, Vesole DH, Jagannath S, Kaminski M, Cole C, Nam J, Stephens LA, Rosebeck S, et al. Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimid®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM) Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.320 |
0.283 |
|
| 2015 |
Jakubowiak AJ, Griffith K, Jasielec JK, Rosenbaum CA, Berdeja JG, Vij R, Raje N, Reece D, Rosebeck S, Gurbuxani S, Dytfeld D, Zimmerman TM. Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared with KRd without ASCT in newly diagnosed multiple myeloma (NDMM) Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.173 |
0.283 |
|
| 2013 |
Dytfeld D, Kandarpa M, Rosebeck S, Jasielec J, Strahler J, Mellacheruvu D, Subramani S, Kraftson S, Alonge M, Ngoka L, Nesvizhskii A, Sreekumar A, Richardson P, Komarnicki M, Jakubowiak A. Thioredoxin domain containing 5 (TXNDC5) as a marker of response in multiple myeloma – validation studies of proteomic profiling Acta Haematologica Polonica. 44: 38. DOI: 10.1016/J.Achaem.2013.07.294 |
0.27 |
|
| 2016 |
Rosebeck S, Lim MS, Elenitoba-Johnson KS, McAllister-Lucas LM, Lucas PC. API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis. World Journal of Biological Chemistry. 7: 128-37. PMID 26981201 DOI: 10.4331/Wjbc.V7.I1.128 |
0.203 |
|
| Hide low-probability matches. |